Warning: The NCBI web site requires JavaScript to function. more...
High-density lipoprotein: does it have a dark side?
Von Feldt JM.
Arthritis Res Ther. 2008;10(5):121. Epub 2008 Oct 31.
Related citations
The role of high-density lipoprotein in inflammation.
Navab M, Anantharamaiah GM, Fogelman AM.
Trends Cardiovasc Med. 2005 May;15(4):158-61. Review.
Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis.
Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, Grijalva V, Hama S, Kozak K, Buga G, Whitelegge JP, Lee TD, Farias-Eisner R, Navab M, Fogelman AM, Reddy ST.
J Biol Chem. 2007 Aug 10;282(32):23698-707. Epub 2007 Jun 7.
The paradox of dysfunctional high-density lipoprotein.
Ansell BJ, Fonarow GC, Fogelman AM.
Curr Opin Lipidol. 2007 Aug;18(4):427-34. Review.
Multiple actions of high-density lipoprotein.
Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP.
Curr Opin Cardiol. 2008 Jul;23(4):370-8. Review.
The anti inflammatory effects of high density lipoproteins.
Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ.
Curr Med Chem. 2009;16(6):667-75. Review.
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis.
Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M.
Arthritis Res Ther. 2008;10(4):213. Epub 2008 Aug 29. Review.
Targeting the anti-inflammatory effects of high-density lipoprotein.
Ansell BJ.
Am J Cardiol. 2007 Dec 3;100(11 A):n3-9. Review.
HDL metabolism and activity in chronic kidney disease.
Vaziri ND, Navab M, Fogelman AM.
Nat Rev Nephrol. 2010 May;6(5):287-96. Epub 2010 Mar 23. Review.
[The biology of HDL lipoprotein and its antisclerotic activity].
Kuliszkiewicz-Janus M, Mohamed AS, Abod N.
Postepy Hig Med Dosw (Online). 2006;60:307-15. Review. Polish.
Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications.
Cho KH.
BMB Rep. 2009 Jul 31;42(7):393-400. Review.
High-density lipoprotein function recent advances.
Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC.
J Am Coll Cardiol. 2005 Nov 15;46(10):1792-8. Epub 2005 Oct 19. Review.
Modifying the anti-inflammatory effects of high-density lipoprotein.
Ansell BJ, Fonarow GC, Navab M, Fogelman AM.
Curr Atheroscler Rep. 2007 Jan;9(1):57-63. Review.
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA.
J Lipid Res. 2010 Aug;51(8):2058-73. Epub 2010 Apr 6. Review.
High-density lipoproteins, inflammation and oxidative stress.
Tabet F, Rye KA.
Clin Sci (Lond). 2009 Jan;116(2):87-98. Review.
Antiatherogenic functionality of high density lipoprotein: how much versus how good.
Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P.
J Atheroscler Thromb. 2008 Apr;15(2):52-62. Epub 2008 Apr 3. Review.
Oral amphipathic peptides as therapeutic agents.
Reddy ST, Anantharamaiah GM, Navab M, Hama S, Hough G, Grijalva V, Garber DW, Datta G, Fogelman AM.
Expert Opin Investig Drugs. 2006 Jan;15(1):13-21. Review.
Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
Nofer JR, Walter M, Assmann G.
Expert Rev Cardiovasc Ther. 2005 Nov;3(6):1071-86. Review.
Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides.
Petraki MP, Mantani PT, Tselepis AD.
Curr Pharm Des. 2009;15(27):3146-66. Review.
The enigmatic duality of high-density lipoprotein-cardioprotective yet potentially atherogenic: comment on the article by McMahon et al.
Leow MK.
Arthritis Rheum. 2007 Feb;56(2):696-7. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on